MAPT and Alzheimer disease: The current biological categorization of Alzheimer’s disease commonly relies on other data sources such as amyloid- or tau-sensitive PET scans or cerebrospinal fluid (CSF) biomarkers, all of which are more invasive than structural brain MRI.